AbbVie Makes Progress on Quest to Diversify
AbbVie's (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Fortunately, there's still time to develop blockbuster drugs that can help offset any eventual slowing in Humira demand.
Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
AbbVie Inc. Stock
€170.56
1.510%
The stock is an absolute favorite of our community with 32 Buy predictions and no Sell predictions.
As a result the target price of 178 € shows a slightly positive potential of 4.36% compared to the current price of 170.56 € for AbbVie Inc..
